Luton, Bedfordshire, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) — Market Overview
The global interventional pulmonology device market is projected to reach USD 6.2 billion in 2024 and is expected to exceed USD 10 billion by 2034, growing at a CAGR of approximately 6.3%. The market’s expansion is primarily driven by:
- The increasing prevalence of respiratory diseases
- A growing geriatric population
- Technological advancements in minimally invasive pulmonary procedures
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/65319/global-interventional-pulmonology-device-market#request-a-sample
Key Market Drivers (Detailed)
- Rising Incidence of Respiratory Conditions
- Chronic Obstructive Pulmonary Disease (COPD) affects over 390 million people globally, with high prevalence in aging and smoking populations.
- Asthma cases are steadily rising, especially among children and in urban settings due to pollution.
- Lung cancer, often diagnosed late, requires advanced bronchoscopic biopsies—driving demand for diagnostic tools and navigation systems.
- Aging Population
- As global life expectancy increases, so does the aging population (65+), who are more susceptible to respiratory diseases due to declining lung function.
- Geriatric patients require minimally invasive diagnostic and therapeutic options, such as robotic-assisted bronchoscopy and cryotherapy tools.
- Innovation in Bronchoscopic Technologies
- Robotic-assisted bronchoscopy (e.g., Ion by Intuitive Surgical) allows for precise navigation into peripheral lung lesions.
- AI-powered imaging systems help detect lesions, assist in real-time decision-making, and reduce false negatives.
- Integration with 3D imaging and electromagnetic navigation improves procedural success rates.
- Favorable Regulatory Trends
- Agencies like the FDA and EMA are expediting approvals for innovative minimally invasive devices.
- Coverage expansion by insurance companies for bronchial thermoplasty and navigational bronchoscopy is encouraging adoption.
- Increased government grants and public-private partnerships supporting lung cancer screening programs.
Market Challenges (Detailed)
- High Procedure Costs
- Advanced equipment like robotic bronchoscopes and navigation systems cost hundreds of thousands of dollars.
- Limited adoption in developing nations and smaller hospitals due to high capital and maintenance costs.
- Reimbursement Complexities
- Variability in insurance coverage across countries creates uncertainty for providers and patients.
- Some emerging procedures lack proper coding or are not included in standard coverage schemes, hampering widespread use.
- Regulatory Hurdles
- Interventional pulmonology devices often face long and expensive clinical trial requirements, particularly for Class III devices.
- Cross-border regulatory harmonization remains a challenge for manufacturers expanding globally.
- Supply Chain Disruptions
- The COVID-19 pandemic revealed fragility in global supply chains—impacting availability of scopes, catheters, and components.
- Ongoing geopolitical tensions, raw material shortages, and dependency on single-source suppliers remain key risks.
Growth Opportunities (Detailed)
- AI & Smart Bronchoscopy Devices
- Companies are integrating machine learning algorithms to analyze real-time bronchoscopic video for better diagnosis.
- Smart catheters and scopes now include sensors that provide feedback on tissue interaction, force, and navigation.
- Expanding Use Cases
- Beyond cancer, bronchoscopic tools are being used for:
- Infectious disease diagnostics (e.g., TB, fungal infections).
- Sleep apnea treatment via upper airway stimulation.
- Interstitial lung disease biopsy with minimal trauma.
- Growing interest in therapeutic applications like localized drug delivery and stent placement.
- Beyond cancer, bronchoscopic tools are being used for:
- Surging Healthcare Investments
- Asia-Pacific is projected to grow at CAGR ~8%, driven by:
- Increasing government health budgets (India, China).
- Rapid expansion of private hospitals.
- Rising awareness about early lung disease detection.
- Asia-Pacific is projected to grow at CAGR ~8%, driven by:
- Strategic Collaborations
- Partnerships between device manufacturers and tech firms (e.g., AI developers, imaging companies).
- Licensing deals and co-development agreements enhancing R&D capabilities.
- Collaborations with academic institutions accelerating innovation in diagnostics and surgical training tools.
Market Segmentation
By Product Type
The interventional pulmonology devices market is segmented into bronchoscopes, biopsy forceps, endobronchial valves, bronchial dilators, stents, and other devices. Bronchoscopes hold the largest market share, estimated at around 30%, driven by the growing adoption of robotic-assisted systems that allow for enhanced precision, especially in lung cancer diagnostics and treatment. Biopsy forceps account for about 10% of the market, supported by advances that increase tissue sampling accuracy for early cancer detection. Endobronchial valves, making up 15% of the market, are vital for lung volume reduction procedures in COPD patients. Bronchial dilators (20% share) are in high demand due to their role in airway stenosis management. Stents contribute approximately 12% of the market, with innovations such as self-expanding and drug-eluting designs driving their growth. The remaining 13% includes various specialized tools like navigational aids, cryoprobes, and catheters, used in advanced diagnostic and therapeutic interventions.
| Product Type | Estimated Share (%) | Key Trends |
| Bronchoscopes | 30% | Increasing adoption of robotic systems |
| Biopsy Forceps | 10% | Enhanced precision in lung cancer diagnostics |
| Endobronchial Valves | 15% | Key in lung volume reduction procedures |
| Bronchial Dilators | 20% | Demand driven by airway management needs |
| Stents | 12% | Innovations in self-expanding and drug-eluting designs |
| Other Devices | 13% | Includes navigational aids and catheters |
By Application
In terms of application, oncology represents the largest segment, accounting for around 45% of the market. This dominance is attributed to the rising global burden of lung cancer and the increasing use of bronchoscopy for early detection, biopsy, and treatment. Respiratory diseases, including COPD and asthma, follow with a 30% share, fueled by aging populations and increasing environmental risk factors. Infectious diseases, such as tuberculosis and pneumonia, make up 15% of the market, with flexible bronchoscopy playing a central role in accurate diagnosis and treatment. Sleep apnea, with a 10% share, is an emerging application area benefiting from growing awareness, diagnostics, and minimally invasive interventional therapies such as airway stimulation and dilation.
| Application | Share (%) |